<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03811951</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1288</org_study_id>
    <nct_id>NCT03811951</nct_id>
  </id_info>
  <brief_title>Neuro Biomarkers of Smoking Behavior</brief_title>
  <official_title>Neurologic Biomarkers of Smoking Behavior</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate cognition in smokers and nonsmokers. It involves
      administration of intranasal insulin (Novolin R), an investigational medication followed by a
      brief non-invasive cognitive test, during which brain waves are recorded. All participants
      will receive both Novolin R and placebo in two separate testing sessions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This program of research focuses on identifying neurologic biomarkers of smoking behavior in
      order to develop individualized smoking cessation aids. The intranasal insulin administered
      is an investigational drug and has been granted IND status by the FDA (IND#129432). During
      the times of drug effects, the investigators will evaluate a biomarker using non-invasive
      equipment. Non-smokers and smokers will participate in two testing sessions where the
      biomarker will be critically evaluated after administration of intranasal insulin and
      compared to the cognitive processes elicited by placebo administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2018</start_date>
  <completion_date type="Anticipated">September 12, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The University of Illinois Hospital and Health Sciences System Investigational Drug Service (IDS) randomizes treatment order to study subjects and prepares drug product and placebo. All other roles, including participant, investigator, and non-IDS study personnel are masked from treatment order.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>P300</measure>
    <time_frame>From time of drug administration to 70 minutes following drug administration</time_frame>
    <description>P300 is an event-related potential component associated with decision making during a cognitive task. P300 is measured in electroencephalogram (EEG) recordings as a waveform of brain voltage changes over time. The amplitude of this waveform, averaged over multiple trials, is indicative of cognitive processes involved in attention and stimulus classification. P300 is observed in the range of 250-500ms following presentation of a visual stimulus.
EEG recording occurs each experimental session approximately 30 minutes following intranasal insulin administration. Each EEG session lasts approximately 70 minutes.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive both Novolin R (experimental drug) and 14% NaCl (Sodium Chloride) solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive both Novolin R (experimental drug) and 14% NaCl solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novolin R</intervention_name>
    <description>Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.</description>
    <arm_group_label>Non-Smokers</arm_group_label>
    <arm_group_label>Smokers</arm_group_label>
    <other_name>McKesson Corporation, Novo Nordisk</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 21-40 years

          -  Smokers only: Begin smoking within 5 minutes of waking (verified by carbon monoxide
             concentrations greater than 10 ppm).

          -  Non-smokers only: No self-reported cigarette use in the past 1-year period.

          -  Non-smokers only: Carbon monoxide concentration &lt; 6 ppm.

          -  Normal vitals (blood pressure &lt; 120/80 mmHg; heart rate between 60 and 100 bpm, body
             temperature &lt;37 °C)

          -  Point-of-care (POC) blood glucose between 80 and 140 mg/dL

          -  Body mass index between 18.5 and 30 kg/m2

        Exclusion Criteria:

          -  Use of non-cigarette tobacco products, e-cigarettes, or smoking cessation treatment

          -  Positive urine drug screen test

          -  Current pregnancy (urine test-verified) or lactation, or a plan to become pregnant

          -  Breath Alcohol Concentration &gt;0.00%

          -  Shipley IQ (Intelligence Quotient) test &lt;80

          -  Hyposmic or anosmic individuals (identifying less than 10 of 12 smells correctly)

          -  Abnormal physical exam of the nares

          -  Lifetime DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5) Axis 1
             disorder (except anxiety and depression)

          -  Current DSM-5 Axis depression or anxiety disorder

          -  Prescription medications

          -  Over-the-counter psychotropic medications

          -  Use of any medications administered intranasally

          -  Allergies to any ingredients in intranasal insulin or placebo

          -  Braided hair that would cause noise in EEG recording
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajna Hamidovic, PharmD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ajna Hamidovic, PharmD, MS</last_name>
    <phone>312-355-1713</phone>
    <email>ahamidov@uic.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yohyoh Wang</last_name>
    <phone>312-996-8838</phone>
    <email>yohyoh@uic.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Illinois Department of Pharmacy Practice</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajna Hamidovic, PharmD</last_name>
      <phone>312-355-1713</phone>
      <email>ahamidov@uic.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yohyoh Wang</last_name>
      <phone>(312) 996-8838</phone>
      <email>yohyoh@uic.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997 Jun;29(7):1422-31. Review.</citation>
    <PMID>9180099</PMID>
  </reference>
  <reference>
    <citation>de la Monte SM. Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art. Expert Opin Drug Deliv. 2013 Dec;10(12):1699-709. doi: 10.1517/17425247.2013.856877. Epub 2013 Nov 12. Review.</citation>
    <PMID>24215447</PMID>
  </reference>
  <reference>
    <citation>Fehm HL, Perras B, Smolnik R, Kern W, Born J. Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology? Eur J Pharmacol. 2000 Sep 29;405(1-3):43-54. Review.</citation>
    <PMID>11033313</PMID>
  </reference>
  <reference>
    <citation>Franken IH, van Strien JW, Kuijpers I. Evidence for a deficit in the salience attribution to errors in smokers. Drug Alcohol Depend. 2010 Jan 15;106(2-3):181-5. doi: 10.1016/j.drugalcdep.2009.08.014. Epub 2009 Sep 24.</citation>
    <PMID>19781864</PMID>
  </reference>
  <reference>
    <citation>Hamidovic A, Khafaja M, Brandon V, Anderson J, Ray G, Allan AM, Burge MR. Reduction of smoking urges with intranasal insulin: a randomized, crossover, placebo-controlled clinical trial. Mol Psychiatry. 2017 Oct;22(10):1413-1421. doi: 10.1038/mp.2016.234. Epub 2017 Feb 28.</citation>
    <PMID>28242873</PMID>
  </reference>
  <reference>
    <citation>Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes. 1999 Mar;48(3):557-63.</citation>
    <PMID>10078556</PMID>
  </reference>
  <reference>
    <citation>Luijten M, van Meel CS, Franken IH. Diminished error processing in smokers during smoking cue exposure. Pharmacol Biochem Behav. 2011 Jan;97(3):514-20. doi: 10.1016/j.pbb.2010.10.012. Epub 2010 Oct 31.</citation>
    <PMID>21047524</PMID>
  </reference>
  <reference>
    <citation>Nedelcovych MT, Gadiano AJ, Wu Y, Manning AA, Thomas AG, Khuder SS, Yoo SW, Xu J, McArthur JC, Haughey NJ, Volsky DJ, Rais R, Slusher BS. Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ACS Chem Neurosci. 2018 Apr 18;9(4):809-816. doi: 10.1021/acschemneuro.7b00434. Epub 2018 Jan 4.</citation>
    <PMID>29257872</PMID>
  </reference>
  <reference>
    <citation>Ott V, Benedict C, Schultes B, Born J, Hallschmid M. Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. Diabetes Obes Metab. 2012 Mar;14(3):214-21. doi: 10.1111/j.1463-1326.2011.01490.x. Epub 2011 Nov 16. Review.</citation>
    <PMID>21883804</PMID>
  </reference>
  <reference>
    <citation>Rass O, Fridberg DJ, O'Donnell BF. Neural correlates of performance monitoring in daily and intermittent smokers. Clin Neurophysiol. 2014 Jul;125(7):1417-26. doi: 10.1016/j.clinph.2013.12.001. Epub 2013 Dec 11.</citation>
    <PMID>24380760</PMID>
  </reference>
  <reference>
    <citation>Reger MA, Craft S. Intranasal insulin administration: a method for dissociating central and peripheral effects of insulin. Drugs Today (Barc). 2006 Nov;42(11):729-39. Review.</citation>
    <PMID>17171192</PMID>
  </reference>
  <reference>
    <citation>Schmid V, Kullmann S, Gfrörer W, Hund V, Hallschmid M, Lipp HP, Häring HU, Preissl H, Fritsche A, Heni M. Safety of intranasal human insulin: A review. Diabetes Obes Metab. 2018 Jul;20(7):1563-1577. doi: 10.1111/dom.13279. Epub 2018 Apr 6.</citation>
    <PMID>29508509</PMID>
  </reference>
  <reference>
    <citation>Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab. 2012 Feb;97(2):366-76. doi: 10.1210/jc.2011-1802. Epub 2011 Dec 7. Review.</citation>
    <PMID>22162476</PMID>
  </reference>
  <reference>
    <citation>Strachan MW. Insulin and cognitive function in humans: experimental data and therapeutic considerations. Biochem Soc Trans. 2005 Nov;33(Pt 5):1037-40. Review.</citation>
    <PMID>16246040</PMID>
  </reference>
  <reference>
    <citation>West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl). 2000 Apr;149(3):198-202.</citation>
    <PMID>10823399</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2019</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Ajna Hamidovic</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Tobacco</keyword>
  <keyword>Cigarettes</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Insulin</keyword>
  <keyword>Electroencephalogram</keyword>
  <keyword>EEG</keyword>
  <keyword>Event-Related Potential</keyword>
  <keyword>ERP (Event-Related Potential)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT03811951/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

